Cytokinetics (NASDAQ: CYTK) revenue
Cytokinetics reported revenue of $88.0m for fiscal 2025, 376.6% more than in fiscal 2024 ($18.5m). Since fiscal 2016 its revenue has fallen by 17.3%, an average decline of 2.1% a year.
Cytokinetics has grown its revenue for 2 years in a row, and its best year of the last 10 was fiscal 2016. The biggest drop was in fiscal 2023, −92.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $88.0m | +376.6% | −$612.3m | −695.4% |
| 2024 | $18.5m | +145.3% | −$536.2m | −2,902.7% |
| 2023 | $7.5m | −92.0% | −$496.2m | −6,589.7% |
| 2022 | $94.6m | +34.3% | −$324.2m | −342.8% |
| 2021 | $70.4m | +26.2% | −$186.3m | −264.5% |
| 2020 | $55.8m | +107.8% | −$93.9m | −168.3% |
| 2019 | $26.9m | −14.7% | −$98.9m | −368.0% |
| 2018 | $31.5m | +135.6% | −$88.9m | −282.3% |
| 2017 | $13.4m | −87.4% | −$113.4m | −848.3% |
| 2016 | $106.4m | — | $18.7m | 17.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Cytokinetics revenue compared with its sector
By revenue for its latest fiscal year, Cytokinetics ranks 293rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Cytokinetics, 376.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 291st | Siga Technologies | $94.6m | −31.8% |
| 292nd | CeriBell | $89.1m | 36.1% |
| 293rd | Cytokinetics | $88.0m | 376.6% |
| 294th | Delcath Systems | $85.2m | 129.1% |
| 295th | 4D Molecular Therapeutics | $85.2m | 230,194.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Cytokinetics
- How much revenue did Cytokinetics make in fiscal 2025?
- Cytokinetics reported revenue of $88.0m for fiscal 2025, compared with $18.5m in fiscal 2024.
- How much has the revenue of Cytokinetics fallen?
- Between fiscal 2016 and fiscal 2025 it went from $106.4m to $88.0m: 17.3% less, an average decline of 2.1% a year.
- What was the best year for revenue at Cytokinetics?
- Of its last 10 fiscal years, fiscal 2016, with $106.4m.
- Where does Cytokinetics rank in its sector by revenue?
- It ranks 293rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Cytokinetics come from?
- From the annual report (Form 10-K) that Cytokinetics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Cytokinetics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Cytokinetics: the Cytokinetics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.